SUPN
Supernus Pharmaceuticals Inc
42.70$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.3% | 22.2% | 31.1% | 37.9% | 31.5% | 36.4% | 26.6% | 21.9% | 17.5% | 18.3% | 26.0% | 6.6% | |
| 0.8% | 0.6% | 1.1% | 2.7% | 1.7% | 1.7% | 3.5% | 5.6% | 12.8% | 14.0% | 12.2% | 12.5% | |
| 2.2% | 2.9% | 2.8% | 2.8% | 2.8% | 3.8% | 3.2% | 3.1% | 2.6% | 4.4% | 4.2% | 4.6% | |
| 2.1% | 4.3% | -16.6% | 9.9% | 1.7% | 2.3% | 3.1% | 3.4% | -1.6% | – | – | – | |
| -14.3% | 7.0% | 3.9% | 7.8% | -1.2% | 0.2% | -7.0% | 0.6% | -3.6% | -1.5% | -0.3% | -10.5% | |
| 0.5% | 1.5% | 0.7% | 0.7% | 0.2% | 0.7% | 0.7% | 0.4% | 0.1% | 0.1% | 0.1% | 0.2% | |
| -4.0% | -25.1% | -16.7% | -28.6% | -101.1% | -40.2% | -6.7% | -14.1% | -32.5% | 44.2% | -28.7% | 0.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.5% | 1.3% | 1.0% | 1.9% | 18.9% | 1.0% | 0.8% | 1.2% | 1.9% | -0.3% | – | – | |
| 0.0% | 278.7% | 187.2% | 133.2% | 95.9% | -0.2% | -0.2% | -23.9% | 0.0% | -66.3% | 0.0% | 0.0% | |
| 0.5% | 1.3% | 1.0% | 1.9% | 92.1% | 1.0% | 0.7% | -22.5% | -1.6% | -65.5% | 1.8% | 1.3% | |
| 2.8% | -1.6% | 15.3% | 11.2% | 22.5% | -2.8% | 20.6% | -14.7% | -16.5% | -3.0% | -0.9% | 8.4% | |
| 5.9% | 20.8% | 30.3% | 37.3% | 31.3% | 35.7% | 25.9% | 21.6% | 17.4% | 18.2% | 25.9% | 6.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.